CER Daily Newsfeed

Stakeholders Emphasize Pharma's Role After ICER Launch Price Report

(10/31, Luke Zarzecki, Inside Health Policy) reports “...Kimberly Westrich, the National Pharmaceutical Council's chief strategy officer, said in a statement to Inside Health Policy the ICER report ignored market dynamics. ‘It's disappointing that this new report is another ICER effort that does more harm than good due to a host of methodological, data, and analytic shortcomings,’ she said. ‘Start with the focus on launch pricing; it ignores actual market dynamics and fails to capture the full value medicines provide over their lifecycle to patients, health systems, and society.’ Westrich also said the report did not include ‘underspending’ on drugs for those priced below ICER's HBPB.” Subscription Required

PCORI Establishes Comparative Clinical Effectiveness Research Advisory Panel

(10/31, The PCORI Blog) comments “...This panel will advise on the planning, development, implementation and refinement of PCORI’s efforts to fund patient-centered CER. Specifically, this new panel will: Identify patient-centered CER questions and topics for possible funding initiatives. Advise on priorities for communicating and disseminating PCORI-funded research findings. Advise on potential strategies for PCORI-funded dissemination and implementation efforts. Review and comment on PCORI’s funded research portfolio and provide feedback on potential research methods and study designs.” Full

What’s Next for HEOR? Rob Abbott Reflects on the Road to ISPOR Europe 2025

(10/31, The Evidence Base) reports “...[ISPOR CEO Rob Abbott:] With respect to evidence generation and methodology, I’ll just mention two key issues: (1) how can RWE be designed to achieve a level of validity comparable to randomized controlled trials (RCT)? And (2) what are best practices for causal inference methods? On the regulatory and payer decision making side of things, we need to figure out how RWE can be incorporated into regulatory submissions and HTA/payer decisions to complement RCT data. On the economic evaluation front, there are several important methodological questions but one I’m looking forward to digging into at ISPOR Europe 2025 is how real-world data might improve the accuracy and relevance of cost-effectiveness models by providing real-world resource use, adherence and persistence data.” Full